MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
0.6300
-0.0500 (-7.35%)
At close: Jun 27, 2025, 4:00 PM
0.6500
+0.0200 (3.17%)
After-hours: Jun 27, 2025, 7:39 PM EDT
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,727,667
Market Cap
12.33M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
MTVA News
- 7 days ago - MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session - PRNewsWire
- 18 days ago - MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th - GlobeNewsWire
- 24 days ago - MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions - PRNewsWire
- 6 weeks ago - MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - PRNewsWire
- 7 weeks ago - MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PRNewsWire
- 2 months ago - MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PRNewsWire
- 2 months ago - MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - PRNewsWire